Özge Uluçkan, Elizabeth A. Morgan, Angela C. Hirbe, and Chapter 82: Skeletal Complications of Breast and Prostate Cancer Therapies Özge Uluçkan, Elizabeth A. Morgan, Angela C. Hirbe, and Katherine Weilbaecher

From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Figure 1 Figure 1 Extent of bone loss caused by cancer therapy. Healthy men lose bone at a rate of 0.5%/yr beginning at middle age, whereas menopausal women lose bone at a rate of 1–2%/yr. Cancer treatments such as AI therapy, ADT, and chemotherapy accelerate this process, leading to significant bone loss and subsequent skeletal complications.(6,16,18,49,50) (Printed with permission from Postgraduate Institute for Medicine and Interlink Healthcare Communications, joint sponsors of the CME Lecture Series titled Skeletal Complications Across the Cancer Continuum. Slide/Lecture Kit release date: June 2005.) Figure 1 Extent of bone loss caused by cancer therapy. Healthy men lose bone at a rate of 0.5%/yr beginning at middle age, whereas menopausal women lose bone at a rate of 1–2%/yr. Cancer treatments such as AI therapy, ADT, and chemotherapy accelerate this process, leading to significant bone loss and subsequent skeletal complications.(6,16,18,49,50) (Printed with permission from Postgraduate Institute for Medicine and Interlink Healthcare Communications, joint sponsors of the CME Lecture Series titled Skeletal Complications Across the Cancer Continuum. Slide/Lecture Kit release date: June 2005.)